AstraZeneca’s (AZN) Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of adults with resectable non-small cell lung cancer at high risk of recurrence and no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, the company announced. In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery. The Committee for Medicinal Products for Human Use of the European Medicines Agency based its positive opinion on results from the pivotal AEGEAN trial, the company noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Growth Potential Highlighted by Positive Risk-Reward Scenario and Strategic Drug Portfolio
- AstraZeneca added to European Conviction List at Goldman Sachs
- Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire
- AIM announces principal investigator for Ampligen, FluMist clinical study
- AstraZeneca Enhertu recommended for approval in EU by CHMP